NEW YORK (GenomeWeb) – PerkinElmer said after the close of the market on Thursday that its first quarter revenues were up 5 percent year over year.

The Waltham, Mass.-based company said that for the three months ended March 30, revenues grew to $531.9 million from $505.4 million in the year-ago quarter, edging out the consensus analyst estimate of $531.3 million.

Its Human Health segment posted a 6 percent increase in revenue year over year to $299.5 million from $281.3 million, while its Environmental Health segment grew 4 percent to $232.4 million from $224.0 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.